Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer's disease (AD), Parkinson's disease (PD) and other chronic neurodegenerative diseases. Co. is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. The ANVS average annual return since 2020 is shown above.
The Average Annual Return on the ANVS average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ANVS average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ANVS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ANVS Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
